|
Apr 26
|
OptimizeRx Provides Business Update and Sets First Quarter 2024 Conference Call for May 14, 2024 at 4:30 p.m. ET
|
|
Apr 23
|
After Plunging -22.84% in 4 Weeks, Here's Why the Trend Might Reverse for OptimizeRx (OPRX)
|
|
Apr 22
|
Down -18.75% in 4 Weeks, Here's Why You Should You Buy the Dip in OptimizeRx (OPRX)
|
|
Apr 18
|
OptimizeRx Releases 2024 Environmental, Social, and Governance (ESG) Report
|
|
Apr 16
|
OptimizeRx Reports Strong Fourth Quarter and Full Year 2023 Financial Results
|
|
Apr 11
|
OptimizeRx Named America’s Fastest-Growing Company for Fifth Year in a Row
|
|
Apr 6
|
7 Top Undervalued Stocks Primed for a Multibagger Recovery
|
|
Apr 1
|
OptimizeRx Corporation (NASDAQ:OPRX) Q4 2023 Earnings Call Transcript
|
|
Mar 25
|
OptimizeRx Sets Fourth Quarter 2023 Conference Call for March 28, 2024 at 8:30 a.m. ET
|
|
Mar 11
|
OptimizeRx Provides an Update on the Timing of Earnings Call and Reaffirms Prior Revenue and Adjusted EBITDA Estimates for FY2023
|
|
Mar 4
|
OptimizeRx Powers Walmart's ‘Specialty Pharmacies of the Community’ Outreach Effort
|
|
Jan 9
|
OptimizeRx Preannounces Select Expected 2023 Financials and Provides a Business Update
|
|
Dec 18
|
OptimizeRx to Participate at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco
|
|
Dec 6
|
Wall Street Analysts Predict a 41.25% Upside in OptimizeRx Corp. (OPRX): Here's What You Should Know
|
|
Aug 24
|
OptimizeRx Expands AI Powered Omnichannel Platform
|
|
Aug 20
|
OptimizeRx Corporation (NASDAQ:OPRX) Analysts Just Trimmed Their Revenue Forecasts By 13%
|
|
May 4
|
Investing in OptimizeRx (NASDAQ:OPRX) five years ago would have delivered you a 114% gain
|
|
May 2
|
Surveyed Physicians Spell Out Preferences for Data-driven, Omnichannel Content That Delivers Clinical Relevance
|